Diurnal today announces that Martin Whitaker, PhD has been appointed as its new Chief Executive Officer and Director of the Company.
Martin has previously held the position of General Manager within Diurnal. He brings to the role, as CEO of Diurnal, a strong track record of innovation, a detailed understanding of the orphan drug marketplace and an extensive network of contacts.
Commenting on the appointment, Kevin Bryett, Diurnal Chairman said:
"Martin has an in depth understanding of Diurnal's objectives and has been instrumental in Diurnal's growth to date. I am very pleased that he has accepted the role of CEO of Diurnal as we look to continue to progress our lead product Chronocort® through to registration"